Re-Publication. Notwithstanding anything to the contrary in this Article 7, the contents of any press release or other publication that has been reviewed and approved by a reviewing Party in accordance with this Article 7 may be re-released by such reviewing Party or publishing Party without a requirement for re-approval.
Appears in 1 contract
Sources: Exclusive License Agreement (Day One Biopharmaceuticals, Inc.)
Re-Publication. Notwithstanding anything to the contrary in this Article 7Section 11.1, the contents of any press release or other publication that has been reviewed and approved by a reviewing Party in accordance with this Article 7 Section 11.1 may be re-released by such reviewing Party or publishing Publishing Party without a requirement for re-approval.
Appears in 1 contract
Sources: License and Collaboration Agreement (Stoke Therapeutics, Inc.)
Re-Publication. Notwithstanding anything to the contrary in this Article 7, the The contents of any press release or other publication that has been reviewed and approved by a reviewing Party in accordance with this Article 7 Section 7.5.1 or Section 7.6 may be re-released by such reviewing Party or publishing Party without a requirement for re-approval, including the repeat of any information regarding the terms of this Agreement that has already been publicly disclosed by such Party, or by the other Party in accordance with Section 7.5.1.
Appears in 1 contract
Sources: Exclusive License Agreement (Day One Biopharmaceuticals, Inc.)
Re-Publication. Notwithstanding anything to the contrary in this Article 710, the contents of any press release or other publication that has been reviewed and approved by a reviewing Party in accordance with this Article 7 10 may be re-released by such reviewing Party or publishing Party without a requirement for re-approval.
Appears in 1 contract
Sources: License and Collaboration Agreement (Sutro Biopharma, Inc.)